These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 35776657)

  • 1. Applications of molecular barcode sequencing for the detection of low-frequency variants in circulating tumour DNA from hepatocellular carcinoma.
    Lee HW; Kim E; Cho KJ; Park HJ; Seo J; Lee H; Baek E; Choi JR; Han KH; Lee ST; Park JY
    Liver Int; 2022 Oct; 42(10):2317-2326. PubMed ID: 35776657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
    Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
    Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments.
    Campani C; Imbeaud S; Couchy G; Ziol M; Hirsch TZ; Rebouissou S; Noblet B; Nahon P; Hormigos K; Sidali S; Seror O; Taly V; Ganne Carrie N; Laurent-Puig P; Zucman-Rossi J; Nault JC
    Gut; 2024 Oct; 73(11):1870-1882. PubMed ID: 39054058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma.
    Wu X; Li J; Gassa A; Buchner D; Alakus H; Dong Q; Ren N; Liu M; Odenthal M; Stippel D; Bruns C; Zhao Y; Wahba R
    Int J Biol Sci; 2020; 16(9):1551-1562. PubMed ID: 32226301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma.
    von Felden J; Craig AJ; Garcia-Lezana T; Labgaa I; Haber PK; D'Avola D; Asgharpour A; Dieterich D; Bonaccorso A; Torres-Martin M; Sia D; Sung MW; Tabrizian P; Schwartz M; Llovet JM; Villanueva A
    Oncogene; 2021 Jan; 40(1):140-151. PubMed ID: 33097857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma.
    Oversoe SK; Clement MS; Weber B; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J
    BMC Cancer; 2021 Apr; 21(1):376. PubMed ID: 33827453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.
    Liao W; Yang H; Xu H; Wang Y; Ge P; Ren J; Xu W; Lu X; Sang X; Zhong S; Zhang H; Mao Y
    Oncotarget; 2016 Jun; 7(26):40481-40490. PubMed ID: 27248174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized circulating tumor DNA in patients with hepatocellular carcinoma: a pilot study.
    Pommergaard HC; Yde CW; Ahlborn LB; Andersen CL; Henriksen TV; Hasselby JP; Rostved AA; Sørensen CL; Rohrberg KS; Nielsen FC; Rasmussen A
    Mol Biol Rep; 2022 Feb; 49(2):1609-1616. PubMed ID: 34811635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib.
    Fujii Y; Ono A; Hayes CN; Aikata H; Yamauchi M; Uchikawa S; Kodama K; Teraoka Y; Fujino H; Nakahara T; Murakami E; Miki D; Okamoto W; Kawaoka T; Tsuge M; Imamura M; Chayama K
    J Exp Clin Cancer Res; 2021 Jun; 40(1):215. PubMed ID: 34174931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma.
    Ikeda S; Tsigelny IF; Skjevik ÅA; Kono Y; Mendler M; Kuo A; Sicklick JK; Heestand G; Banks KC; Talasaz A; Lanman RB; Lippman S; Kurzrock R
    Oncologist; 2018 May; 23(5):586-593. PubMed ID: 29487225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor DNA mutation analysis: advances in its application for early diagnosis of hepatocellular carcinoma and therapeutic efficacy monitoring.
    Yang J; Lin N; Niu M; Yin B
    Aging (Albany NY); 2024 Jul; 16(14):11460-11474. PubMed ID: 39033781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment.
    Sogbe M; Bilbao I; Marchese FP; Zazpe J; De Vito A; Pozuelo M; D'Avola D; Iñarrairaegui M; Berasain C; Arechederra M; Argemi J; Sangro B
    Clin Mol Hepatol; 2024 Apr; 30(2):177-190. PubMed ID: 38163441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma.
    Weng J; Atyah M; Zhou C; Ren N
    Clin Exp Med; 2020 Aug; 20(3):329-337. PubMed ID: 32239299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of MET gene somatic mutations in hepatocellular carcinoma of Egyptian patients using next-generation sequencing.
    Ahmed E; El-Dien A N; Sabet S; Khalifa M; El Hamshary M
    Biomarkers; 2023 Jun; 28(4):379-386. PubMed ID: 36825430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma.
    Cai Z; Chen G; Zeng Y; Dong X; Li Z; Huang Y; Xin F; Qiu L; Xu H; Zhang W; Su X; Liu X; Liu J
    Clin Cancer Res; 2019 Sep; 25(17):5284-5294. PubMed ID: 31217202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Use of ctDNA in the Diagnosis and Monitoring of Hepatocellular Carcinoma-Literature Review.
    Kopystecka A; Patryn R; Leśniewska M; Budzyńska J; Kozioł I
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma.
    Labgaa I; Villacorta-Martin C; D'Avola D; Craig AJ; von Felden J; Martins-Filho SN; Sia D; Stueck A; Ward SC; Fiel MI; Mahajan M; Tabrizian P; Thung SN; Ang C; Friedman SL; Llovet JM; Schwartz M; Villanueva A
    Oncogene; 2018 Jul; 37(27):3740-3752. PubMed ID: 29628508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular Carcinoma.
    Lyu X; Tsui YM; Ho DW; Ng IO
    Cell Mol Gastroenterol Hepatol; 2022; 13(6):1611-1624. PubMed ID: 35183803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.
    Ikeda S; Lim JS; Kurzrock R
    Mol Cancer Ther; 2018 May; 17(5):1114-1122. PubMed ID: 29483209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Tumor DNA Clinical Applications in Hepatocellular Carcinoma: Current Trends and Future Perspectives.
    Bardol T; Pageaux GP; Assenat E; Alix-Panabières C
    Clin Chem; 2024 Jan; 70(1):33-48. PubMed ID: 37962158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.